Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 12, Pages 5245-5256Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00085
Keywords
-
Categories
Ask authors/readers for more resources
The lipid kinase phosphoinositide 3-kinase gamma (PI3K gamma) has attracted attention as a potential target to treat a variety of autoimmune disorders, including multiple sclerosis, due to its role in immune modulation and microglial activation. By minimizing the number of hydrogen bond donors while targeting a previously uncovered selectivity pocket adjacent to the ATP binding site of PI3K gamma, we discovered a series of aza-isoindolinones as selective, brain penetrant inhibitors of PI3K gamma. This ultimately led to the discovery of 16, an orally bioavailable compound that showed efficacy murine experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available